bioRxivMicrobiologyPreprint
Application and comparison of lyophilisation protocols to enhance stable long-term storage of filovirus pseudotypes for use in antibody neutralisation tests
M. Mayora Neto, E. Wright, N. J. Temperton, P. Soema, R. ten Have, I. Ploemen, S. D. Scott
Abstract
Filoviruses encompass highly pathogenic viruses placing sporadic public health burden on countries affected. Efforts for improved diagnostics and surveillance are needed considering the recent Ebola outbreaks in Africa. The need for high containment facilities can be circumvented by the use of pseudotype viruses (PV), which can be handled in low containment, for tropism, drug screening, vaccine immunogenicity and serosurveillance studies. In this study we assessed stability and functionality after long-term storage of lyophilised filovirus pseudotypes for use in neutralisation assays. Lyophilised Ebola and Marburg PVs retained production titres for at least two years when stored at +4{degrees}C or less. Lyophilised Ebola PVs performed similarly to non-lyophilised PVs in neutralisation assays after reconstitution. When stored at high temperatures (+37{degrees}C), lyophilised PVs did not retain titres after one-month storage, however, when lyophilised using pilot scale facilities EBOV PVs retained titres and performed well in neutralisation assays after one-month storage at 37{degrees}C suggesting removing residual moisture might be crucial for avoiding cold-chain transportation. Lyophilisation could allow reagents to be transported more efficiently as well as reducing costs for a future serological kit.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A virion-based assay for glycoprotein thermostability reveals key determinants of filovirus entry and its inhibition
R. H. Bortz, A. C. Wong, … K. Chandran·bioRxiv·Feb 25, 2020
- Low-dose VSV-EBOV vaccination provides rapid protection from lethal Ebola virus challenge
Andrea Marzi, Wakako Furuyama, … Heinz Feldmann·bioRxiv·Feb 15, 2026
- Rational design of next-generation filovirus vaccines through glycoprotein stabilization, nanoparticle display, and glycan modification
Yi-Zong Lee, Yi-Nan Zhang, … Jiang Zhu·bioRxiv·Mar 2, 2025
- IgY antibodies against Ebola virus possess post-exposure protection and excellent thermostability
- Thin-Film Freeze-Drying of a Norovirus Vaccine Candidate
H. Xu, T. Bhowmik, … Z. Cui·bioRxiv·Jun 8, 2021
- A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus